Table 1 |
||||
|
Details of the patients and medication at the time of surgery |
||||
|
Groups |
Active RA |
Inactive RA |
OA |
Normal |
|
|
||||
|
Age (years) |
62.5 ± 19.28 |
72.33 ± 7.07 |
69.22 ± 7.98 |
36.3 ± 10.39 |
|
|
||||
|
Gender (male/total) |
2/10 |
6/9 |
6/9 |
6/10 |
|
|
||||
|
CRP (IU/mL) |
83.90 ± 83.78 |
9.78 ± 8.21 |
NA |
NA |
|
|
||||
|
RF (mg/L) |
19.40 ± 44.10 |
1.44 ± 0.53 |
<20 |
NA |
|
|
||||
|
Erosion Positivity per total samples |
2/10 |
2/9 |
0/9 |
0/9 |
|
|
||||
|
DMARDS |
NSAIDs 9 Prednisolone 1 |
SSZ 1 Im Gold 5 MTX 2 Plaquenil 1 |
No NSAIDs 5 Panadeine 1 NSAIDs 3 |
None 9 Allopurinol 1 |
|
|
||||
|
CRP, C-reactive protein; DMARD, disease modifying antirheumatic drug; Im Gold, intramuscular sodium aurothiomalate; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; SSZ, sulphasalazine |
||||
|
Crotti et al. Arthritis Research & Therapy 2012 14:R245 doi:10.1186/ar4088 |
||||